 The AI agent market: public company stock growth creates a window for major investments In recent weeks, shares of companies developing agentic AI have shown steady growth amid a wave of news about the adoption of autonomous agents in the corporate sector. Investors are actively reassessing the valuation of this segment—and this is not hype, but a structural shift. What is happening: — Major public players in the AI agent space have gained an average of 10–15% over the month — Corporations are mass-testing AI agents for automating business processes — The autonomous AI systems market is estimated by analysts at tens of billions of dollars by 2028 ASI Biont's position: Unlike companies creating 'horizontal' general-purpose assistants, ASI Biont focuses on a narrow but explosive direction—AI biotechnologies. We are building an ecosystem of agents specialized in analyzing bioinformatics data, medical research, and automating R&D processes. This gives us a unique advantage: 1. High barrier to entry for competitors—deep expertise at the intersection of AI and biology 2. Growing demand from pharmaceuticals, biotech, and scientific institutions 3. Ability to scale into adjacent verticals For investors from $1 million: The growth of the public market confirms: the AI agent market is not speculation, but a new industrial reality. ASI Biont offers entry into this trend at a stage when multipliers are not yet 'heated up,' and the technological foundation is already built. [https://asibiont.com/](https://asibiont.com/) New users get 1500 tokens to start for getting acquainted with the platform.